ABVX

#4743
Abivax SA American Depositary Shares
121.28
+1.95%
Sector:
Básica:
Profit Currency:
Rango diario
121.28
121.28
Rango anual
4.77
148.83
Cambio diario
+1.95%
Monthly Change
+2.15%
6 month change
+54.14%
Cambio anual
+1532.30%
Cierres anteriores
118.96
Open
121.28
Bid
Ask
Low
121.28
High
121.28
Volumen
43
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
  • Market Capitalization N/A
  • Employee 67
  • Founded 2013
  • CEO Hartmut J. Ehrlich
  • Website www.abivax.com
  • Headquarter France
  • FIGI BBG01JLQNZ03
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
—
Price to sales ratio
—
Dividends per share
—
Dividend yield %
—

Abivax SA - American Depositary Shares

Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated. The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France.

Noticias